Search | Browse by Day | Author Index

Author Index: F

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Fagerlin, A.
  • TO HAVE OR NOT TO HAVE PSA TEST? IS THE DECISION AFFECTED BY WHETHER INFORMATION IS PRESENTED SEQUENTIALLY VS. ALL-AT-ONCE?
  • CONCURRENT ORAL SESSION C: MEDICAL EDUCATION AND DECISION AIDS
  • INFORMATION OVERLOAD IN BREAST CANCER DECISION MAKING: WHEN TWO CHOICES ARE TOO MANY
    • Fagerlin, A.
  • COLOSTOMY IS BETTER THAN DEATH, BUT A 4% CHANCE OF DEATH MIGHT BE BETTER THAN A 4% CHANCE OF COLOSTOMY: WHY PEOPLE MAKE CHOICES SEEMINGLY AT ODDS WITH THEIR STATED PREFERENCES
    • Falco, E. M.
  • SUSPICION REQUIRED
  • INCOMPLETE PHYSICAL EXAMINATION
    • Fang, C.
  • OBSERVED VERSUS RECOMMENDED PATIENT PRESCRIPTION REFILL BEHAVIOUR - ASSESSMENT OF ADALIMUMAB AND ETANERCEPT PRESCRIPTION GAPS FOR THE FIRST YEAR OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
    • Fang, C.
  • WILLINGNESS TO PAY FOR PREDICTIVE DIAGNOSTIC INFORMATION WITH NO IMMEDIATE TREATMENT IMPLICATIONS: A SURVEY OF U.S. RESIDENTS
    • Fard, M.
  • SET-VALUED DYNAMIC TREATMENT REGIMES
    • Farrell, R. M.
  • RISK AND UNCERTAINTY: SHIFTING DECISION-MAKING FOR ANEUPLOIDY SCREENING TO THE FIRST TRIMESTER OF PREGNANCY
  • NEW TECHNOLOGY, NEW CHALLENGES: BARRIERS TO INFORMED DECISION-MAKING FOR FIRST TRIMESTER ANEUPLOIDY SCREENING
    • Farris, C.
  • COST-EFFECTIVENESS OF SEXUAL ASSAULT PREVENTION PROGRAMS: POTENTIAL UTILITY OF TARGETED TREATMENT FOR HIGH-RISK MEN
    • Feenstra, T.
  • COMMUNICATING UNCERTAINTY IN GENERALIZED COST-EFFECTIVENESS ANALYSES: VISUALIZING OPTIMAL INTERVENTIONS AND STRATEGIES
    • Feibelmann, S.
  • TREATING HIP AND KNEE OSTEOARTHRITIS: DO PATIENTS WHO CHOOSE SURGERY MAKE BETTER DECISIONS?
    • Feinberg, D.
  • PATIENT'S FACIAL APPEARANCE ALTERS LIKELIHOOD OF PROVIDING MEDICAL TREATMENT
    • Feldman, B. M.
  • THE COST-EFFECTIVENESS OF BIOLOGICS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS PATIENTS UNRESPONSIVE TO DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    • Feldman-Stewart, D.
  • INTRODUCTION TO DESIGNING EVIDENCE-BASED PATIENT DECISION AIDS
  • THE IMPACT OF VALUES CLARIFICATION IN A DECISION AID: EVIDENCE FROM A RANDOMIZED CONTROLLED TRIAL EMERGES SLOWLY OVER TIME
    • Fendrick, A. M.
  • NYSTAGMUS ASSESSMENTS DOCUMENTED BY EMERGENCY PHYSICIANS IN ACUTE DIZZINESS PRESENTATIONS: A TARGET FOR DECISION SUPPORT?
    • Fenwick, E. A.
  • COST-EFFECTIVENESS OF GENE EXPRESSION PROFILING IN EARLY BREAST CANCER
  • PRINCIPLES AND PRACTICES OF PERSON-LEVEL COST-EFFECTIVENESS ANALYSIS
  • A PROBABILISTIC DECISION MODEL TO GUIDE OPTIMAL HEALTH POLICY DECISIONS FOR LUNG CANCER SCREENING
    • Fergusson, D.
  • CAN IPDAS CRITERIA BE USED TO ASSESS THE QUALITY OF INFORMED CONSENT DOCUMENTS?
    • Ferket, B. S.
  • PERSONALIZED PREVENTION OF CORONARY ARTERY DISEASE
  • DO DIFFERENT METHODS OF MODELING STATIN EFFECTIVENESS INFLUENCE THE OPTIMAL DECISION?
    • Ferreira, J. C.
  • COST-EFFECTIVENESS ANALYSIS OF 48- VERSUS 24-HOUR METHYLPREDNISOLONE INTERVENTION IN SPINAL CORD INJURY PATIENTS
    • Ferrusi, I.
  • COST-EFFECTIVENESS OF GENE EXPRESSION PROFILING IN EARLY BREAST CANCER
  • PUBLISHED ECONOMIC EVIDENCE TO SUPPORT PERSONALIZED MEDICINE DECISION-MAKING: THE EXAMPLE OF HER2-POSITIVE EARLY BREAST CANCER
    • Festinger, D.
  • DO RESEARCH PAYMENTS INCREASE PERCEIVED COERCION? INITIAL RESULTS OF A NOVEL FINANCIAL INCENTIVE COERCION ASSESSMENT INSTRUMENT
    • Feudtner, C.
  • PERFORMANCE OF HEAD CIRCUMFERENCE PERCENTILE CUTOFFS
    • Finlayson, S. R.
  • COST-EFFECTIVENESS OF USING ADHESION BARRIERS DURING SURGERY TO PREVENT RE-OPERATIONS FOR SMALL BOWEL OBSTRUCTION
    • Finnell, S. M. E.
  • HEALTH UTILITIES IN PEDIATRIC COST-UTILITY STUDIES
    • Fisman, D. N.
  • IS A MASS IMMUNIZATION PROGRAM FOR PANDEMIC (H1N1) 2009 GOOD VALUE FOR MONEY? EVIDENCE FROM THE CANADIAN EXPERIENCE
  • INTRODUCTION TO INFECTIOUS DISEASE TRANSMISSION MODELS
    • Fleming, M.
  • DIAGNOSTIC ERRORS ARE COMMON CAUSES OF ADVERSE EVENTS IN HOSPITALIZED CANADIAN CHILDREN
    • Fletcher, K.
  • THE NUMERACY UNDERSTANDING IN MEDICINE INSTRUMENT (NUMI): A NEW MEASURE OF HEALTH NUMERACY DEVELOPED USING ITEM RESPONSE THEORY
    • Flintoft, V.
  • DIAGNOSTIC ERRORS ARE COMMON CAUSES OF ADVERSE EVENTS IN HOSPITALIZED CANADIAN CHILDREN
    • Flocke, S. A.
  • RISK AND UNCERTAINTY: SHIFTING DECISION-MAKING FOR ANEUPLOIDY SCREENING TO THE FIRST TRIMESTER OF PREGNANCY
    • Fonseca, K.
  • EFFECTS OF SCHOOL CLOSURE ON PANDEMIC INFLUENZA INCIDENCE IN 2009
    • Forman, J.
  • NYSTAGMUS ASSESSMENTS DOCUMENTED BY EMERGENCY PHYSICIANS IN ACUTE DIZZINESS PRESENTATIONS: A TARGET FOR DECISION SUPPORT?
    • Forward, K.
  • POLYMERASE CHAIN REACTION TESTS FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN HOSPITALIZED PATIENTS: CLINICAL AND COST-EFFECTIVENESS ANALYSES
    • Fournier, D. L.
  • OPTIMIZING THE NUMBER OF NEONATAL INTENSIVE CARE UNIT BEDS IN BRITISH COLUMBIA
    • Fowler, R. A.
  • IS A MASS IMMUNIZATION PROGRAM FOR PANDEMIC (H1N1) 2009 GOOD VALUE FOR MONEY? EVIDENCE FROM THE CANADIAN EXPERIENCE
    • Fox, C.
  • CLINICAL UNCERTAINTY AND RISK AVERSION ARE ASSOCIATED WITH PRIMARY CARE PROVIDER REFERRAL OF PATIENTS WITH SEVERE KIDNEY DISEASE TO NEPHROLOGY
    • Franek, J.
  • NON-INVASIVE CARDIAC IMAGING TECHNOLOGIES FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: A MEGA-HTA TO INFORM POLICY DECISION MAKING
  • PHARMCOGENETIC TESTING AND EVIDENCE-BASED DECISION-MAKING IN ONTARIO: THE APPLICATION OF ONTARIO'S DECISION DETERMINANTS FRAMEWORK TO THE EVALUATION OF PHARMACOGENETIC TESTS
    • Freedberg, K. A.
  • THRESHOLDS FOR COST-EFFECTIVENESS OF ADDING AN AGENT THAT IMPROVES IMMUNE RESPONSES TO INITIAL ANTIRETROVIRAL THERAPY (ART) IN HIV-INFECTED PATIENTS: GUIDANCE FOR DRUG DEVELOPMENT
  • PATIENT- AND POPULATION-LEVEL HEALTH CONSEQUENCES OF DISCONTINUING ANTIRETROVIRAL THERAPY (ART) IN RESOURCE-LIMITED SETTINGS
  • A COST-EFFECTIVENESS ANALYSIS OF GENOTYPE DRUG RESISTANCE TESTING AT FAILURE OF 1ST-LINE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS IN SOUTH AFRICA
    • French, M.
  • DO RESEARCH PAYMENTS INCREASE PERCEIVED COERCION? INITIAL RESULTS OF A NOVEL FINANCIAL INCENTIVE COERCION ASSESSMENT INSTRUMENT
    • Frick, K. D.
  • AN INTERPROFESSIONAL APPROACH TO UNDERSTANDING DECISION MAKING FOR TREATMENT OF CHRONIC VISUAL IMPAIRMENT: A NEW CONCEPTUAL MODEL
  • WHICH MEN WITH LOW-RISK PROSTATE CANCER SHOULD BE TREATED?
  • PHARMACY LOCATION CORRELATION WITH FILLS OF INHALED CORTICOSTEROIDS IN URBAN CHILDREN WITH ASTHMA
    • Frimannsdottir, K. R.
  • PERSONALIZED PREVENTIVE MEDICINE AND ITS CONSEQUENCES: THE IMPACT OF PREDICTIVE GENOMIC TESTING ON RISK PERCEPTION AND WORRY
    • Fromer, L.
  • AN INNOVATIVE APPROACH TO ADDRESSING DIAGNOSTIC ERRORS AND SHARED DECISION MAKING
    • Frosch, D.
  • PATIENT'S SALIENT BELIEFS ABOUT COMMUNICATING AND MAKING DECISIONS WITH PHYSICIANS
  • PROMOTING USE OF PATIENT DECISION SUPPORT INTERVENTIONS IN A LARGE COMMUNITY-BASED MULTI-SPECIALTY GROUP PRACTICE
  • SHARED DECISION MAKING BEHAVIOURS IN FAMILY MEDICINE RESIDENTS
    • Fuhrel-Forbis, A.
  • IMPRECISE DEFINITIONS OF “PRECISE”: PREFERENCES FOR PRECISION DEPEND ON CONTEXT
  • INFORMATION OVERLOAD IN BREAST CANCER DECISION MAKING: WHEN TWO CHOICES ARE TOO MANY
  • COLOSTOMY IS BETTER THAN DEATH, BUT A 4% CHANCE OF DEATH MIGHT BE BETTER THAN A 4% CHANCE OF COLOSTOMY: WHY PEOPLE MAKE CHOICES SEEMINGLY AT ODDS WITH THEIR STATED PREFERENCES
    • Fukagawa, M.
  • COST-EFFECTIVE TREATMENT THRESHOLDS FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN
    • A B C D E F G H I J K L M N O P Q R S T U V W X Y Z